Tomographie à émission de positons et lymphomes |
| |
| Authors: | R Hustinx G Jerusalem B Deprijk |
| |
| Institution: | 1. Service de médecine nucléaire, CHU de Liège, B35, campus du Sart-Tilman, 4000 Liège, Belgique;2. Service d’oncologie médicale, CHU de Liège, B35, campus du Sart-Tilman, 4000 Liège, Belgique;3. Service d’hématologie, CHU de Liège, B35, campus du Sart-Tilman, 4000 Liège, Belgique;1. CHU le Bocage, hématologie clinique, 14, rue Paul-Gaffarel, 21000 Dijon, France;2. Inserm umr1037, Cancer Research Center of Toulouse, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France;3. Inserm UMR866, faculté de médecine, 7, boulevard Jeanne-d’Arc, BP 27877, 21078 Dijon cedex, France;1. Department of Internal Medicine, Cleveland Clinic Florida, Weston, Florida;3. Department of Infectious Disease, Cleveland Clinic Florida, Weston, Florida;4. Department of Gastroenterology and Hepatology, Cleveland Clinic Florida, Weston, Florida;1. Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, 42271 Saint-Priest-en-Jarez cedex, France;2. Institut Gustave-Roussy, département d’innovations thérapeutiques et d’essais précoces, 94805 Villejuif, France;3. CHU Estaing, centre Jean-Perrin, service d’hématologie, département de médecine oncologique, 63000 Clermont-Ferrand, France;4. Assistance publique–Hôpitaux de Paris, hôpital Saint-Antoine, service d’oncologie médicale, 75012 Paris, France;5. Centre Léon-Bérard, département d’oncologie médicale, 69000 Lyon, France;6. Institut Paoli-Calmettes, département d’oncologie médicale, 13000 Marseille, France;7. Institut Curie, département d’oncologie pédiatrique-adolescents-jeunes adultes, 75005 Paris, France;8. Assistance publique–Hôpitaux de Paris, hôpital Tenon, service de pneumologie et de réanimation, 75020 Paris, France;9. Centre Antoine-Lacassagne, département de radiothérapie, 06000 Nice, France;10. Centre Oscar-Lambret, 59000 Lille, France;11. Hôpitaux de Chartres, service oncologie hématologie, , site Louis-Pasteur, 28630 Chartres-Le-Coudray, France;1. Biosensor National Special Lab, Key Lab for Biomedical Engineering of Ministry of Education, Department of Biomedical Engineering, Zhejiang University, 310027 Hangzhou, China;2. Zhejiang Sir Run Run Shaw Hospital, Department of Medicine, Zhejiang University, 310027 Hangzhou, China |
| |
| Abstract: | There is an abundant literature dealing with FDG PET imaging in lymphomas and Hodgkin's disease. Several meta-analysis are available, along with international recommendations. In this concise review, we will discuss the major indications of the technique. FDG PET/CT imaging should be performed as part of the initial staging of Hodgkin's disease and potentially curable non-Hodgkin's lymphomas, and possibly for the follicular lymphomas as well. Although the clinical impact at initial diagnosis is fairly limited, the initial metabolic picture will be of great value for assessing the response to treatment. Indeed, FDG PET/CT has become the cornerstone for evaluating the disease status after completion of treatment. Although a negative PET study has a very high predictive value and does not need any further confirmation, a positive PET study cannot be relied upon solely to modify the treatment and a confirmatory biopsy should be performed whenever possible. Furthermore, the predictive value of an interim PET study, performed early on during treatment i.e. after two or three courses of chemotherapy, appears very high, probably higher than when the PET is performed after treatment. However, the available data are not sufficient to support altering the treatment scheme depending on the PET results only. Several large studies are nevertheless under way, which should provide further clarifications in the near future. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
